Radoslaw SOBOTA

Radoslaw joined A*STAR IMCB in 2014 to build new projects oriented Joint Functional Proteomics Laboratory established by A*STAR and Nanyang Technological University (NTU), where he implemented, among broad variety of other MS- based expertise, pipeline for MS-based proteome wide drug targets screening (MS-CETSA). In 2015, Radoslaw’s expertise in the field of applied proteomics was recognised and he was awarded with a Young Investigator Grant  to study protein state specific drug targets recognition. He went on to receive a NMRC grant “MS-CETSA platform - for drug discovery” as Co-investigator to establish mass spectrometry based proteome platform for drugs target screening. Since 2018, Radoslaw leads IMCB Functional Proteomics Laboratory. In 2019, his laboratory, together with the National University of Singapore (NUS) was awarded the National Research Foundation (NRF-SIS) grant to set up the Singapore Mass Spectrometry Laboratory (SingMass). SIngMass is Singapore's national laboratory for mass spectrometry, coordinating cutting-edge expertise to expand the analytical capacity of existing facilities into a unique new resource in Singapore. As a founding member of SingMass, Radoslaw is also a member of SingMass Steering committee and SingMass Board of Directors.

Dr. Radoslaw Sobota received his PhD (Dr.rer.nat.) from RWTH-Aachen (2007) in Germany.  His thesis focused on negative regulation of cytokine signal transduction and acute phase response. While at RWTH, he started to develop interest in the application of mass spectrometry based proteomics in signal transduction studies. In 2008 Radoslaw joined the Centre for Experimental Bioinformatics (CEBI) group at University of Southern Denmark in Odense (Denmark) and continued his scientific career together with Prof. Jens Andersen. During his postdoctoral training in Odense, he was involved in industrial collaborations aiming identification of surface membrane biomarkers expressed differentially by antigen presenting cells, with Danish companies and innovative consortia comprising Danish biotech companies and academic partners.